Interview with Ala Ciobanu, General Manager, Roche Ukraine
As a leader responsible for heading Roche’s operations since its establishment of an LLC in Ukraine in 2009, what do you consider have been the main achievements of the company?…
Address: Roche Products Ltd, Hexagon Place, 6 Falcon Way, Welwyn Garden City, Hertfordshire, AL7 1TW, United Kingdom
Tel: +44 (0)1707 366000
Web: http://www.roche.co.uk/portal/uk
Headquartered in Basel, Switzerland, Roche employs around 2,000 people in the UK in pharmaceuticals, based at Welwyn Garden City in Hertfordshire, and diagnostics, based at Burgess Hill in East Sussex.
The UK pharmaceuticals headquarters at Welwyn Garden City in Hertfordshire is home to Roche’ global pharmaceutical product development team, its pharmaceuticals sales and marketing teams and corporate functions.
The purpose built facility that opened in 2005 at Shire Park in Welwyn Garden City, reflects and supports the continued success of Roche’s pharmaceutical business.
In 2006 Roche’ UK diagnostics sales and marketing team relocated to a new purpose-built facility in Burgess Hill, East Sussex.
As the UK’s leading in-vitro diagnostics company, Roche has a dynamic UK sales and marketing team who consistently deliver growth above the market rate.
As one of the major pharmaceutical and diagnostic companies in the UK, Roche develops and provides an innovative range of products and services that help healthcare professionals improve the health and well-being of the UK population.
As a leader responsible for heading Roche’s operations since its establishment of an LLC in Ukraine in 2009, what do you consider have been the main achievements of the company?…
Christine (Chris) Fox, VP general manager UK and Ireland at Amgen discusses the rationale behind taking on the management of a UK affiliate in challenging times and the specificities of…
A spinout from the Roslin Institute that created Dolly the Sheep, Roslin CT is a cell and gene therapy CDMO, with a unique positioning in the field today. Its CEO,…
Jonny Ohlson, founder & CEO of Touchlight, discusses the genetic medicine revolution and the role of Touchlight in disrupting the field with its revolutionary DNA technology. You founded Touchlight Genetics…
Dr. Geoffrey Guy, chairman and founder of cannabinoid medicine pioneer, GW Pharma, outlines the potential benefits that Brexit could bring to the UK’s life sciences industry and the evolution of…
KaNDy Therapeutics, a UK-based biotech has raised £25 million to finance the Phase 2b trial of their breakthrough product in Women’s Health. Our investors and the KaNDy management team are united…
Sterling Pharma Solutions is a rapidly growing GMP contract API manufacturer based out of Dudley, Cramlington in the Northeast of England. The company was set up in its current structure…
Offering genomic sequencing and analysis, Congenica operates in the exciting world of genomic diagnosis, with a particular focus on rare diseases. Its CEO David Atkins describes the potential of Congenica’s…
Sean Richardson discusses Alexion’s focus on rare and ultra-rare diseases, the level of support for these therapies from the UK government, awareness raising, diagnostics, and his future priorities. …
With over 30 years of experience in the life sciences industry, Angela McFarlane explains why the UK will not be removed from its position in the top 3 for new…
For Ipsen, the UK is one of three global hubs, with manufacturing in Wales in which it is continuously investing, as well as large-scale R&D activities near Oxford. Ipsen’s general…
Brexit, Brexit, Brexit. It’s all anyone can talk about and yet nobody can tell you with certainty what to expect. As the UK’s impending withdrawal from the European Union looms…
Professor David Garway-Heath, a specialist in glaucoma, talks with us about the screening devices of the future, low awareness of glaucoma as a chronic disease and collaboration in training and…
See our Cookie Privacy Policy Here
